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Abstract 
 
Chlorpyrifos (CPF), a worlwide used organophosphate pesticide, an acetylcholinesterase 
inhibitor, has proved to be a disruptor of neurodevelopment, even a very low doses. There are 
several studies that found behavioural effects, like compulsivity or worsening in spatial 
learning. In this study, we proved that using a Morris Water Maze protocol, in which rats (as 
animal models) have to find a hidden platform, which protect them from water, in a water-
filled pool using special cues. 2 groups of treatment (CPF-exposed or control) and 2 groups of 
sex (females and males) were made. CPF (or vehicle) was administered from PND10 to 
PND15, and rats were evaluated when were 14 months old. Results showed only a better 
performance in the Reinstating memory task of CPF- exposed rats, and a lower swim velocity. 
This could be due to a possible compensation mechanism that emerged in senectitude or to 
the proved interactions of CPF with steroid hormones metabolism, which may cause 
masculinization in females (and thus a better performance in some cases). 
 
Key-words: Chlorpyrifos, acetylcholinesterase inhibition, spatial learning, senectitude, 
steroid hormones, masculinization, locomotor hypoactivity. 
Resumen 
El clorpirifos (CPF), un pesticida organofosforado usado mundialmente que inhibe la 
acetilcolinesterasa) ha probado ser un factor que altera el neurodesarrollo, incluso a dosis muy 
bajas. Hay estudios sobre efectos conductuales de la exposición a CPF, incluso a dosis muy 
bajas, como por ejemplo conducta compulsiva o déficit de aprendizaje espacial. En este 
estudio medimos esta capacidad mediante el laberinto de agua de Morris, en el que las ratas 
tienen que encontrar una plataforma oculta en una piscina de agua. Se formaron 2 grupos por 
tratamiento (CPF y control) y 2 por sexo (hembras y machos). El CPF (o vehículo) fue 
administrado desde el día posnatal 10 hasta el 15, y la evaluación se realizó cuando tenían 14 
meses de edad. Los resultados mostraron solo un mejor rendimiento en una de las tareas por 
parte de las tratadas con CPF, y una menor velocidad de nado por éstas mismas. Esto podría 
ser debido a mecanismos de compensación que surgen en la senectud o a probadas 
interacciones con hormonas sexuales. 
 
Palabras clave: Clorpirifos, inhibición de la acetilcolinesterasa, aprendizaje espacial, 
senectud, hormonas sexuales, masculinización, hipoactividad locomotora. 
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1. INTRODUCTION 
1.1. Organophosphates 
Organophosphates (OPs) are considered one of the best-known and most used pesticide 
groups worldwide (Barberá, 1989). The first synthesis of a OPs was achieved in the XIX 
century, obtaining, in 1984, tetraethyl pyrophosphate by Philippe de Clermont (Marrs, in 
Karalliedde, Feldman & Henry, 2001). Since then, OPs were more extensively studied by the 
German chemical industry, finding out their powerful pesticide activity and even theorizing a 
possible use as neurochemical weapon. All OPs can be considered as phosphoric acid 
(H3PO4) products, and they can be classified by their chemical structure. Of course, their 
toxicokinetics will depend on those structures. Gupta (2006) reports “at least 13 types of 
OPs”. Chemical structure of phosphoric acid can be seen in Figure 1:  
 
Figure: 1. Chemical structure of phosphoric acid (Retrieved from https://qph.ec.quoracdn.net/main-qimg-
a5d7a8b12e416e684bed1d9ca737f06f) 
Disel, Acikalin, Kekec & Sebe (2016) highlights the high liposolubility and good dermal and 
mucose absorption. The OPs mechanism of action consists in the irreversible inhibition of the 
cholinesterase (ChEs) enzymes, mainly the acetylcholinesterase (AChE) 
(butyrylcholinesterase (BuChE) too), which degrades by hydrolysis the acetylcholine (ACh; a 
neurotransmitter) in the synaptic cleft, giving choline and acetate as products (Carlsson, 
2014). The ChEs activity inhibition produces an excessive accumulation of Ach in the 
synaptic cleft, originating over-activation in neurons with ACh receptors (muscarinic and 
nicotinic receptors). In that way there would exist, at least, 3 clinical categories derived from 
OPs intoxication (Yélamos, Laynez, & Pérez, 1999): 
 Acute cholinergic syndrome: Caused by the overactivation of cholinergic receptors 
(nicotinic and muscarinic), with symptoms like dyspnea, lacrimation, pulmonary edema, 
vomiting, diarrhea, incontinence, increased sweating, bradycardia, etc. There are more 
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symptoms, as cephalea, anxiety or ataxia, derived from affectation if other central nervous 
system (CNS) receptors. 
 Intermediate syndrome: Bleecker (in Karalliedde, Feldman, & Henry, 2001) describes 
it as a clinical profile with a beginning of 1 to 4 days after the cessation of cholinergic 
symptoms (even having been treated pharmacologically). Serious respiratory difficulties can 
be observed, caused by paralysis of cranial nerves controlled muscles. 
 Delayed neuropathy: It’s considered a consequence of the “phosphorylation of an 
enzyme called neurotoxic esterase” (Yélamos, Laynez, & Pérez, 1999). Senanayake (in 
Karalliedde, Feldman, & Henry, 2001) describes it as a clinical profile that begins “about 1 to 3 
weeks after acute exposure, and after a more uncertain interval following chronic exposure”. 
Symptoms are mainly sensory-motor, affecting especially peripheral nerves, with an 
ascendant and retrograde evolution. 
1.2. Chlorpyrifos 
1.2.1. Chemical characteristics and toxicokinetics. 
Chlorpyrifos (clorpirifos in Spanish; O,O-diethyl-O-[3,5,6,-trichloro-2-pyridyl] 
phosphorothioate in chemical nomenclature) or chlorpyrifos-ethyl is a chemical compound, 
xenobiotic, pertaining to the OPs group, currently used as pesticide (insecticide and acaricide) 
worldwide in big crops (Eaton et al., 2008), although there are reports of its utilization for 
biological control of vector-borne diseases (such as malaria, typhus or yellow fever) (Terry et 
al., 2003). It was introduced in market in 1965 (ATSDR, 1997) and it was used as fumigation 
agent in particular houses until 2002, when this use was completely restricted, given its 
probed negative consequences on neurodevelopment (Eaton et al., 2008). However, it still 
being extensively used worldwide (Casida & Quistad, 2004), being present in residual levels 
in a high percentage of foodstuff, due to its powerful pesticide activity in crops (Eaton et al., 
2008). Chlorpyrifos (CPF), as said, belongs to the phosphorotiate sub-group of OPs. 
Generally, when we talk about CPF we are referring to the ethyl-form, existing an alternative 
form, which is less toxic and effective, but equally used and distributed in market, called 
chlorpyrifos-methyl. We show some of its physical-chemical characteristics in Appendix A, 
and we illustrate graphically the chemical structure of CPF in Figure 2, and Compound 
characteristics data are mainly taken from Barberá (1989), Eaton et al. (2008), Registro 
Estatal de Emisiones y Fuentes Contaminantes (n.d.) and Servicio de Prevención de Riesgos 
Laborales de la Universidad de Lleida (n.d.).       
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Figure 2. Chemical structure of CPF (Sigma-Aldrich). 
In respect of the toxicokinetics of CPF (absorption, distribution, metabolism and excretion), it 
must be said that, obviously, factors such as age or species have an important influence. In 
that way, many studies have been carried out, in both humans and animals, and therefore they 
can give us some different data.  Moreover, it must be said that the mainly used metabolite for 
measuring, especially, distribution, metabolism and excretion is 3,5,5-trichloro-2-pyridinol 
(TCPy) (however, diethylthiophosphate (DETP) or diethylphosphate (DEP) are commonly 
used too)). These metabolites are also utilized for measuring the absorption rate. 
 
In relation to the absorption, it has been reported, in experimental animals, maximal levels of 
the previously mentioned metabolites “between 1 and 3 hours” after a CPF administration via 
oral (Timchalk, Busby, Campbell, Needham, & Barr, 2007; Timchalk et al., 2002). On the 
other hand, Nolan, Rick, Freshour, & Sanders (1984; as cited in Eaton et al., 2008) informed 
about “peak TCPy levels (…) after 6 h” in humans. There are data about dermal absorption 
(an important via of occupational exposure). Nolan et al. (1984; as cited in Eaton et al., 2008) 
reports “1.28 +/- 0.75% of the dermal applied dose of chlorpyrifos (…) recovered in the urine 
as metabolites after 24 h, as long as Meuling, Ravensberg, Roza, & van Hemmen (2005) talk 
about a TCPy peak in urine 72 h after the dermal application of 15 mg of CPF in humans. 
 
About the distribution, Eaton et al. (2008) inform about a high lipophilic activity of CPF, and 
therefore a tendency to accumulate in adipose tissues (known in pharmacology as reservoir). 
 
With respect of the metabolism of CPF, we can talk about two main metabolic routes in CPF 
biotransformation: the activation route and the inactivation route, existing authors that argue 
about implication of different organs in each one of these routes (Sultatos, Shao, & Murphy, 
1983). However, the participation of the cytochrome P450 hemeproteins family is essential. 
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On the one hand, activation route consists on the transformation of CPF in an active 
metabolite (which is in fact the actual source of AChE inhibition): chlorpyrifos-oxon 
(Chambers, 1992; Smith et al., 2009). As said, this transformation is mediated and catalysed 
by cytochrome P450, and it’s a reaction of oxidative desulfurization (Sultatos, 1994). 
Inactivation of this metabolite is mediated by the paraoxonase enzyme (PON), which 
originate, by hydrolysis, TCPy and DTP, which are inactive metabolites. Costa and Furlong 
(in Satoh & Gupta, 2010) described a PON1 activity that depends on its different isoforms. 
An important detail is that PON1 levels are especially low in new-borns, needing a period of 
time until it reaches desirable levels, in both humans (Cole et al., 2003) and rodents (Li, 
Matthews, Disteche, Costa & Furlong, 1997). 
 
By the other hand, detoxication or inactivation route consists on the dearylation of CPF, also 
catalysed by cytochrome P450, generating DETP and TCPy as products (Jokanovic, 2001; as 
cited in Eaton et al., 2008). In the Figure 3 we graphically illustrate both metabolic routes 
(note that authors such as Eaton et al. (2008) don’t consider in their drawings the intermediate 
metabolic): 
 
Figure 3.  Activation and inactivation metabolic routes of CPF (Smith et al., 2009). 
 
Finally, it’s worth talking about CPF excretion. The main metabolite excreted by urine is 
TCPy (Smith, Watson and Fisher (1967) estimated a CPF excretion rate of 89% in TCPy. 
Bakke, Feil and Price (1976) also pointed out that “the glucuronide of 3,5,6-TCP was the 
principal urinary metabolite of chlorpyrifos in the rat” (as cited in Nolan et al., 1984). As said, 
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Nolan et al. (1984) also found, in voluntary human subjects, “peak TCPy levels (…) after 6 
h”. In addition, even though CPF excretion is essentially by urine, Hirom, Milburn, Smith and 
Williams (1972) talk about biliary or faecal excretion, too. Moreover, there are other studies 
that found out residues in maternal milk (such as Marty et al., 2007). 
1.2.2. Mechanism of action of CPF and physiological effects 
CPF, as the most part of OP compounds, has got an activity as irreversible inhibitor of 
cholinesterase enzymes, such as AChE or BuChE (this last with a big presence in plasma and 
liver). This inhibition has got as its immediate consequence the excessive accumulation of 
Ach in the synaptic cleft and a subsequent cholinergic over-activation. In this case, CPF has 
to be metabolized in CPF-oxon, the active CPF metabolite, in order to have any effect. CPF-
oxon bonds its phosphoric radical to the esterase site of cholinesterase (ChE), in such a way 
that the enzyme is no more able to hydrolyse and degrade ACh (note that the chemical bond 
between ACh and AChE is in the anionic site). 
Innumerable physiological effects have been described, commonly direct or indirect product 
of the inhibitory activity over the AChE, and amongst those are evident the typical 
parasympathetic-mimetic symptoms derived from the acute exposure to CPF; symptoms 
generally common to those consequent of intoxication by OPs with anti-cholinesterase 
activity. However, there are studies of the potential long-term effects of CPF exposure of 
pregnant women, mainly in very low doses via diet, in fetus neurodevelopment (i.e., in Rauh 
et al., 2006) (we should remember that CPF still being extensively used in crops as pesticide; 
see Eaton et al. 2008). In that way, it has been probed that CPF exposure could cause a long-
term neurotransmission dysfunction in the cholinergic system, by down-regulation of 
muscarinic receptors (Pope, Chakrabortiu, Chapman & Farrar, 1992; Moser et al., 1998), 
although there are authors that find contradictory effects (Jett, Navoa, Beckles & McLemore, 
2001). 
Moreover, it has been established that CPF effects could go beyond AChE inhibition, 
suggesting possible dysfunctions in other neurochemical systems such as the serotonergic 
(Raines, Seidler, & Slotkin, 2001; Aldridge, Levin, Seidler & Slotkin, 2005;  Aldridge, 
Meyer, Seidler, & Slotkin, 2005; Venerosi, Ricceri, Rungi, Sanghez & Calamandrei, 2010), 
GABAergic (Sánchez-Amate, Flores & Sánchez-Santed, 2001; Sánchez-Amate, Davila, 
Cañadas, Flores & Sánchez-Santed, 2002; Cardona, López-Grancha, López-Crespo, Nieto-
Escámez, Sánchez-Santed & Flores, 2006), as can be deduced from Rastogi, Rastogi, Singhal 
& Lapierre (1985); dopaminergic (Aldridge, Meyer, Seidler, & Slotkin 2005; Slotkin & 
Seidler, 2007 (in doses insufficient to inhibit AChE activity, as cited in Venerosi et al., 
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2010)), or even the endocannabinoid (Carr, Borazjany & Ross, 2011) one. In addition, there 
are descriptions of effects such as interferences in cellular signalling cascade (Huff, Corcoran, 
Anderson, & Abou-Donia (1994), as cited in Abou-Donia et al., 2003; Song et al., 1997) or, 
more globally, effects in the cellular division and development (Campbell, Seidler & Slotkin, 
1997). Terry et al. (2007) found anomalies in neurotrophic factors and in axonal transport, 
whereas Slotkin, Brown & Seidler (2005) observed systemic effects such as hyperlypidemia 
and dysfunctions in insulin releasing. By other hand, López-Granero, Cañadas et al. (2013) 
and De Felice, Greco, Calamandrei & Minghetti (2016) have described oxidative stress 
effects of CPF exposure, and Peris-Sampedro et al. (2015) revealed interactions with human 
apolipoprotein E (apoE) polymorphisms.  
1.2.3. Behavioural effects of CPF exposure 
With regard to the behavioural consequences of CPF exposure (with an special emphasis in 
neurodevelopment stages), there are proofs of a possible anxiolytic effect of CPF (Aldridge, 
Levin, Seidler, & Slotkin, 2005; Carr et al., 2011), yet there also are studies with opposite 
results (Sánchez-Amate et al., 2001). It also has been proved that CPF promotes compulsive 
behaviour (Cardona et al., 2006; Montes de Oca et al., 2013). It has been observed alterations 
by locomotor hyperactivity too (Grabovska & Salyha, 2015; Levin et al., 2002; Yan, Jiao, 
Zhao, Yang & Peng, 2012), although other researchers have given contradictory data (Carr et 
al., 2001), surely due to differences in administration and behavioural evaluation 
methodology. Additionally, authors such as Grabovska and Salyha (2015) or Middlemore-
Risher, Buccafusco and Terry (2010) found prototypical ADHD (Attention Deficit 
Hyperactivity Disorder) in rodents exposed to CPF. Moreover, Chanda and Pope (1996) have 
demonstrated changes in instinctive and reflexive behaviour. There are proofs of alterations in 
socio-emotional behaviour, such as those provided by Venerosi et al. (2010). 
Deleterious effects such as those previously mentioned, in rodents, have been replicated in 
cohort studies, mainly summed up by Eaton et al. (2008) or Li, Lowe, McIntosh & Mink 
(2012), who considered that enough evidence has been found think that it can be generalized 
between species. For example, Rauh et al (2006) have reported an increased prevalence of 
mental/motor retardation and ADHD amongst children exposed to CPF. However, these last 
studies are epidemiological, and need experimental evidence to be verified. This evidence is 
provided, mainly, by experimental animal studies, such as those already discussed. 
In respect of the consequences of CPF exposure on spatial learning and spatial memory, it 
must be said that many studies have been carried out, the most part using as paradigm or 
experimental protocol the Morris Water Maze (MWM), basically consisting on a water-filled 
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round pool, in which the animal has to find a platform, commonly invisible, that protect the 
animal from the water (it’s based on the premise that the animal, rodent, has got preference by 
dry rather than wet environment). However, there also are experiments using other protocols, 
like the Radial Arm Maze (ARM), which measures reference and working spatial memory 
(Johnson, Chambers, Nail, Givaruangsawat & Carr, 2009) through the entries of animal in 
different arms (some of them baited) that begin in a central point, in a manner that enter twice 
or more times in the same arm is considered as working memory error, while enter in an arm 
that has never been baited is considered as working memory error. 
In the Appendix B we show the most relevant articles about CPF-exposure and spatial 
learning evaluated with MWM in rodents, while in Appendix C we show data about CPF-
exposure and spatial learning evaluation with ARM. 
About methodology of these studies, it must be noted if exposure to CPF was carried out 
during the neurodevelopment of the subject, given that in this case the different 
neurochemical systems are specially sensible and vulnerable to environmental agents. In 
many cases, authors try to demonstrate, in addition to the spatial learning deficit, concomitant 
damage in hippocampal areas, such as in Terry et al. (2003), Gómez-Giménez et al. (2017) or 
Mullins et al. (2013), which is postulated as cause of the spatial learning dysfunction. 
Locomotor activity is also commonly evaluated in this studies, such as in Yan et al. (2012). 
However, it must be said that available data are contradictory, although this contradictory data 
could be reflect of different administration, dosage and behavioural evaluation methodologies. 
In that way, Terry et al. (2003) found a worse spatial learning with low doses, in the same 
direction of another study organised by the author (Terry, Beck, Warner, Vandenhuerk, & 
Callahan, 2012). Gómez-Giménez et al. (2017) also described spatial learning alterations after 
a prolonged prenatal CPF exposure. Also in Spain, Sánchez-Santed, Cañadas, Flores, López-
Grancha, & Cardona (2004) observed a worse performance in MWM task after 2 sub-acute 
CPF expositions. A year later, Cañadas, Cardona, Dávila, & Sánchez-Santed (2005)  only 
found an unstable learning curve in CPF-treated rats in comparison to control rats. There are 
some articles amongst these studies in which AChE wasn’t significantly inhibited (such as in 
Yan et al., 2012), with the consequent causal implications.  
We also have to talk about researches organised by López-Granero. In 2013, López-Granero, 
Cañadas, et al. found a worse performance in spatial learning of rats treated with a single dose 
of CPF, in the Reversal task of MWM (which basically measures cognitive flexibility), a short 
time after exposure. However, the same year López-Granero, Cardona, Giménez, Lozano, 
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Barril, Sánchez-Santed et al. didn’t observe this deleterious effect when rats were exposed 
with low doses in a prolonged time. In 2014, López-Granero, Cardona, Giménez, Lozano, 
Barril, Aschner et al. treated rats with a sub-acute dose, finding almost no differences 72 after 
exposure, yet they did find it 23 weeks later. At last, López-Granero, Ruiz-Muñoz et al. 
(2016) didn’t find evidence of any worsening in spatial learning after a prolonged exposure 
period, with low doses and a 7 months washout. 
Moreover, Jett et al. (2001) described a worse spatial learning performance in weaned rats 
exposed to CPF, which didn’t show any significant AChE inhibition. Mullins et al. (2015) 
also registered dysfunction in spatial learning performance in a MWM task, in rats prenatally 
CPF-exposed (though we have to note that they used a breed which haven’t got the same 
neurodevelopment periods as Wistar rats, mainly used in studies described in the two 
paragraphs above), additionally presenting structural brain anomalies. Furthermore, 
Mamczarz et al. (2016) also observed spatial learning deficit after prenatal CPF-exposure. 
However, as long as we know, there are no studies limiting CPF administration, in low doses 
(NOAEL, “no-observable-adverse-effect levels; see Eaton et al., 2008), to the short postnatal 
period in which processes of synaptogenesis are developed; as well as evaluating spatial 
learning (with a MWM protocol) when rats are in late adulthood (almost senectitude). Our 
hypothesis is that early postnatal exposure, in synaptogenesis stage, to CPF levels not enough 
to inhibit ChEs in a significant way (see, for example, Yan et al., 2013) will have, as 
consequence, a worse spatial learning and memory performance than control rats, all 
measured through a MWM protocol in the late adulthood age. 
2. MATERIALS AND METHOD 
2.1. Animals 
20 Time-pregnant females Wistar rats arrived to our facilities at 5 days to parturition. They 
were fed ad libitum and water was disposed as well for free access. 19 out of the 20 rats gave 
birth.  A total of 190 neonates (50% females) were pseudo-randomly distributed to their 
definitive dam, with a total of 10 neonates (50% females) for each mother. Neonates were 
sexed on PND1 (the day of redistribution), PND4, PND9 (one day before exposure protocol 
started) and, finally, at PND21 (weaning day). On PND21, young animals were weaned and 
pseudo-randomized redistributed (rats at the same home-cage must be of the same sex, from 
different original mother and from different assigned Dam) 4 per home-cage, in a temperature 
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and humidity controlled room (22 +/- 2 º C; 50 +/- 10%) and a light/dark cycle of 12 hours 
(13:30h/01:30 h). For this experimental protocol, 32 animals (50% females) were chosen. 
Experiment began when rats were on PND 10 in respect of treatment administration, whereas 
spatial learning evaluation protocol began when rats were 14 months old. From PND 70, they 
received a restricted food diet (13 g per male and 11 g per female), and water ad libitum. Food 
per animal was increased, from the beginning of spatial training tasks, to 14g per male and 
12g per female. Rats weighted a mean of 356,68g (𝜎 = 72,95) the immediately previous week 
to the beginning of spatial training evaluation (by sex, females weighted a mean of 297,27g 
(𝜎 = 10,01) and males a mean of 412,38g (𝜎 = 12,25)). Procedures were approved by the 
animal bioethics committee of the University of Almería, and they were adjusted to the 
Spanish Royal Decree 53/2013 of 1 February and to the Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on experimental animal 
protection and comfort. 
2.2.  CPF administration and dosage 
CPF was purchased as PESTANAL®, from Sigma-Aldrich (ref. no. 45395; purity > 99%). 
Animals were divided into 2 different groups depending on the treatment (CPF group or 
control group), and into 2 groups depending on the sex (female or male). Thus, there were 4 
sub-groups (CPF-female, CPF-male, control-female and control-male), each one with 8 rats. 
CPF in experimental condition was administered via gavage in a dose of 1 mg/kg (not enough 
to cause significant ChEs inhibition; see Yan et al. (2003)), dilute in corn oil, whereas rats in 
control condition only received corn oil (vehicle) via gavage, too. Both CPF and vehicle were 
administered daily from PND 10 to PND 15. 
2.3. Apparatus 
Spatial learning and memory were measured in a round black pool, height of 50 cm and 
diameter or 150 cm, filled with clear water, and maintained in a constant temperature between 
22 and 23 º C. There were 12 holes in the pool base, which allowed to place a black escape 
platform (height of 38,5 cm and diameter of 10 cm). The pool was divided into 4 quadrants 
(A, B, C and D), as the following figure (Figure 4) shows: 
              
Figure 4: Disposition of quadrants in MWM pool. 
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2.4. Procedure in MWM 
2.4.1. Spatial training task (session 1 - 8) 
We have based the spatial learning evaluation methodology on that used by de Bruin, 
Sánchez-Santed, Heinsbroek, Donker & Postmes (1994). We placed a submerged (2,5 cm 
below the water) platform in one of two possible positions, quadrant B or C, in a manner that 
remains invisible for the rat, which have to reach the platform. Each animal was assigned to a 
platform position (B or C), which remained constant in all trials and sessions. The animal was 
released from one of the four quadrants, which remained the same in all animals by each 
session, changing pseudo-randomly between sessions, in a manner that each quadrant was 
used twice in this first phase. The animal had got 90 seconds to reach the platform, and it was 
allowed to remain in there for 30 seconds, completing the trial after that.  In case that the rat 
hadn’t reached, the animal was taken and placed over the platform for 30 seconds too (it 
scored 90 seconds). Each session consisted on 4 trials per animal. Once the 4 trials were 
completed, the rat was dried with a towel and it was put in the cage. One session was carried 
out per day. Escape latency (s), distance moved (cm) and swim velocity (cm/s) were 
measured. 
2.4.2. Transfer test (session 9) 
Platform was removed and rats were allowed to swim freely for 30 seconds. Release point 
was the opposite quadrant to its platform in the Spatial training task (e.g., if rat had had its 
platform in B, its release point in Transfer was quadrant C). Time spent in each quadrant (s), 
distance moved (cm) and swim velocity (cm/s) were measured.  
2.4.3. Reinstating memory (session 10) 
Platform was again placed (submerged) in its original position for each animal, in order to 
carry out for each rat a block of 4 trials, identical to the Spatial learning task. Release point 
was C for all animals in all trials. Time procedure was the same as that one followed in the 
first phase (90 seconds – 30 seconds). Escape latency (s), distance moved (cm) and swim 
velocity (cm/s) were measured. 
2.4.4. Reversal training (session 11 – 13) 
Position of training platform of each animal was inverted, in a way that those who had had 
assigned platform in B changed its target to C (opposite quadrant). Release point varied 
between sessions, but it remained the same for all animals in the 4 trials. 4 trials by session 
per animal were carried out, one session per day. We followed the same time procedure of 
Spatial training task, and we measured the same variables. This task is aimed to measure 
cognitive flexibility. 
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2.4.5. Visually-cued task (session 14 - 16) 
In this task, the platform wasn’t invisible, but remained 1,5 cm over the water (in addition, it 
was grey coloured), in a way that it was visible to the rat. Platform position changed between 
trials, but the sequence of change (e.g. A  B  C D, in session 14) remained the same for 
all animals in each session. This sequence changed between sessions. Release point was the 
opposite quadrant to that which contained the platform (by each animal) in the Spatial training 
task. There was one session per day. We followed the same time procedure of Spatial training 
task, and we measured the same variables, too. 
2.5. Measurements of ChEs activity   
We based our ChEs measurement procedures on Moreno et al. (2008). Firstly, we 
homogenized pellets, at a ratio of 1/10 (w/v), with Triton X-100 (1%), in 0.1 M sodium 
phosphate buffer (pH = 8). Then we centrifuged the homogenate for 15 minutes at 15,000 x g. 
We threw the pellet out, and we used the supernatant to carry out the ChEs assay, of which 
activity was measured using a modification of the Ellman method (Ellman, Courtney, Andres, 
& Featherstone, 1961), utilising a 96-well microplate reader (DTX 880, Beckman Coulter). 
We diluted supernatant with 0.1 M sodium phosphate (pH = 8) (ratio 1/10 (v/v). After that, 
we mixed 10μL of this dilution with 221 μL of sodium phosphate buffer (0.1M, pH = 8) and 
60 μL(in 0.1M sodium phosphate buffer; pH = 8) of 5, 5-dithiobis-2-nitrobenzoic acid (final 
concentration = 0.33mM). We carried out an incubation for 300s (at 37ºC), and then we added 
9 μL of acetylcholine iodide (pH = 8, dilution in 0.1 M sodium phosphate buffer, final 
concentration = 0.5mM). Then, we monitored the reaction rate (at 37ºC) for 22 minutes, and 
measured absorbance at 30 seconds intervals, at 405 nm (3 seconds shake before reading, 45 
cycles). When we analysed slopes, we selected 2 cycles (60 seconds). We calculated the 
enzymatic activity as the rise in absorbance using the equation of Ellman et al. (1961). 
Finally, we measured protein concentration as Bradford (1976). 
2.6. Statistical analysis 
We performed 3 analyses of variance with repeated measures (rmANOVA) in Spatial training 
(+ Reinstating memory), Reversal training y Visually-cued task, with the within-subject 
variable SESSION, and SEX and TREATMENT as between-subject factors. In Transfer task, 
we carried out a multivariate analysis of variance (ANOVA), with POSITION (B or C 
training platform) as co-variable, and SEX and TREATMENT as between-subject factors. We 
used the Sidak correction for multiple comparisons and post-hoc analyses in ANOVA. The 
accepted level of significance for analyses was p ≤ 0,05.  All analyses were performed with 
SPSS Statistics 22 (IBM). 
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3. RESULTS 
3.1. Cholinesterases (ChEs) measurement 
As it can be observed in Figure 5, little inhibition of ChEs on PFC was noticed in CPF 
exposed animals from non-exposed ones. In this way, female rats showed the largest 
inhibition (around 12%), meanwhile males did not reach 7%. Only a soft tendency was 
observed for TREATMENT condition [F (1, 16) = 3.473, p = 0.081], but nothing in 
TREATMENT X SEX interaction [F (1, 16) = 0.319, p = 0.580]. Otherwise, different 
evolution was observed by SEX 6 days after exposure to the xenobiotic had ended, with a 
clear maintenance on ChEs from controls in male rats (6% less compared to control rats), but 
an important "rebound" effect on females (increase of 14% respecting control rats). In this 
way, not even a tendency was observed for TREATMENT [F(1,16)= 0.439, p= 0.517]o such 
TREATMENT X SEX interaction [F(1, 16) = 2.668, p = 0.122]. No significant data was 
obtained with rmANOVA linking both time criteria, but this information is not presented here 
because it was considered by the authors as no appropiate (both days were analysed on 
different plates, thus different Spectrophotometer running).   
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Figure 5.  ChEs activity (% from control) on PND 16 (24h) and PND 21 (6d) by sex. 
 
3.2. Morris Water Maze 
 3.2.1. Spatial training task 
Escape latency (s) was analysed with SESSION as within-subject factor, and SEX and 
TREATMENT as between-subject factors, for CPF-treated group (CPF FEMALES and CPF 
MALES) and control group (CORN FEMALES and CORN MALES). Figure 6 shows the 
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learning curve for all groups. There was significant effect of SESSION [F (7, 189) = 49.788; 
p < 0.001], meaning that rats learnt and performed better the task across sessions. There 
weren’t significant interactions between SESSION and between-subject variables (SESSION 
X SEX [F (7, 189) =1.744, p = 0.101], SESSION X TREATMENT [F (7, 198) = 0.687, p = 
0.683, SESSION X SEX X TREATMENT [F (1, 27) =1.077, p = 0.309]). Moreover, neither 
SEX [F (7, 198) = 0.488, p = 0.842] nor TREATMENT [F (1, 27) = 1.512, p = 0.229] had 
significant effects in escape latency. There wasn’t significant effect of SEX X TREATMENT 
interaction [F (1, 27) =1.077, p = 0.309], either. 
A C Q U IS IT IO N  T A S K
S E S S IO N  (B L O C K S  O F  4  T R IA L S )
E
S
C
A
P
E
 L
A
T
E
N
C
Y
 (
s
)
0 2 4 6 8
0
2 0
4 0
6 0
8 0
1 0 0
C P F  F E M A L E S
C P F  M A L E S
C O R N  F E M A L E S
C O R N  M A L E S
 
Figure 6: Mean escape latencies (s) of each sub-group in the Spatial training phase (session 1 to session 8) and reinstating 
memory task (session 9). 
We also compared, in the Spatial training phase, the 1
st
 and 8
th
 sessions (fig. 7). We only 
found a significant effect of SESSION [F (1, 27) = 210,704, p < 0.01]: rats performed in the 
8
th
 trial better than in the 1
st
 one.. Interactions of this variable with SEX [F (1, 27) = 0.122, p 
= 0.730] and TREATMENT [F (1, 27) = 1, 769, p = 0.195] didn’t have any significance. We 
analysed another within-subject variable, TRIAL, but it didn’t show significant effects [F (3, 
81) = 1,079 p = 0.363]. No significant SESSION X TRIAL interaction effect was found [F (3, 
81) = 0,252, p = 0.860].   On the other hand, we found significant effects of SEX [F (1, 27) = 
5,126, p = 0.032] and SEX X TREATMENT [F (1, 27) = 8,545, p = 0.007], but, since this 
data of escape latencies consisted on the mean of the two sessions, there is no possible 
statistical justification to interpret that. 
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Figure 7: Mean escape latency (s) comparative of session 1 (S1T1 – S1T4) and session 8 (S8T1 – S8T4) (Spatial training 
phase). 
 
 3.2.2. Transfer task 
Multivariate ANOVA analysis was performed for the Transfer test. None significant effect 
was found, neither for TREATMENT [F (4, 24) = 0,496, p = 0.738]   or SEX [F (4, 24) = 
0,642, p = 0.638], nor for the interaction TREATMENT X SEX [F (4, 24) = 0,549, p = 
0.702]. We illustrate the obtained data in Figure 8: 
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Figure 8:  Percent of time spent in each quadrant for each of the 4 sub-groups. We codify the platform trained in Spatial 
training phase as TARGET. 
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 3.2.3.  Reinstating memory task 
In order to evaluate the possible negative effect of the Transfer test (remind that, in that phase, 
platform was removed), we analysed the last session of the Spatial training phase in 
comparison to the Reinstating memory task. We can see the overall results in the Figure 9: 
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Figure 9:  Mean escape latencies (s) in the last session of Spatial training task and in the Reinstating task. 
Overall, there was no significant effect of the within-subject variable S8REINST [F (1, 27) = 
1.955, p = 0.173]. In addition, we didn’t find significant effect of S8REINST X SEX [F (1, 
27) = 0,745, p = 0.496] or S8REINST X TREATMENT X SEX [F (1, 27) = 0,858, p = 
0.362]. However, S8REINST X TREATMENT interaction was significant [F (1, 27) = 4,342, 
p = 0.047]. Post-hoc analyses revealed that rats in control group had got a significantly worse 
performance in the Reinstating memory task when compared to the performance of the last 
session of Spatial training task, hence being negatively affected by the Transfer task. In 
addition, although there wasn’t a significant effect of S8REINST X TREATMEN X SEX, we 
observed that females group had practically the total weight of the lower control group 
performance. Therefore, in females only the CPF treated group did not show a worsening of 
performance after the Transfer task. . In order to know if there was any influence of the trial 
(recall that each session had got 4 trials), we performed a second analysis with the within-
subject variable TRIAL, but we didn’t find any significant effects of this variable [F (3, 81) = 
1,946, p = 0.129]. Effects of interaction weren’t significant, either (TRIAL X SEX: [F (3, 81) 
= 0,246, p = 0.864], TRIAL X TREATMENT: [F (3, 81) = 1,235, p = 0.303], TRIAL X SEX 
X TREATMENT: [F (3, 81) = 0,558, p = 0.645], TRIAL X SESSION: [F (2.264, 61.115) = 
0,750, p = 0.492], TRIAL X SESSION X SEX: [F (2.264, 61.115) = 1,857, p = 0.160], 
TRIAL X SESSION X TREATMENT: [F (2.264, 61.115) = 0,713, p = 0.510], TRIAL X 
SESSION X SEX X TREATMENT: [F (2.264, 61.115) = 0,275, p = 0.787]. In respect of the 
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between-subject variables, none of them showed significant effect (TREATMENT: [F (1, 27) 
= 0,416, p = 0.524], SEX: [F (1, 27) = 0,119, p = 0.732], TREATMENT X SEX: [F (1, 27) = 
0,065, p = 0.800]). 
 3.2.4. Reversal task 
We analysed the data including the within-subject variable TRIAL. Rats had a general 
improvement in its performance across the sessions, as we can see in Figure 10, as SESSION 
effect was significant [F (2, 54) = 8,223, p = 0.001]. TRIAL effect was significant, too [F (3, 
81) = 15,419, p < 0.001]. However, there was neither significant effect of SESSION X 
TRIAL interaction ([F (3.998, 107.954) = 1,137, p = 0.343) nor significant effects of 
SESSION X between-subject variables (SESSION X SEX: [F (2, 54) = 0,499 p = 0.610], 
SESSION X TREATMENT: [F (2, 54) = 0,021, p = 0.979], SESSION X SEX X 
TREATMENT: [F (2, 54) =0,947, p = 0.394]. In respect of the between-subject variables, 
there weren’t significant effects, either (SEX: [F (1, 27) = 0,430, p = 0.517], TREATMENT: 
[F (1, 27) = 0,003 p = 0.958], SEX X TREATMENT: [F (1, 27) = 0,106, p = 0.747].  
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Figure 10:  Mean escape latency (s) by trial and session (S1: T1-4, S2: T5-T8, S3: T9-T12) for each sub-group in Reversal 
task 
 3.2.5. Visually-cued task 
Finally, we show the results (as can be seen in Figure 11) obtained in Visually-cued task. On 
the one hand, there was a general improvement of rats performance between the sessions 
(SESSION: [F (2, 54) = 5,135, p = 0.009]). On the other hand, there wasn’t significant effect 
of any interaction of SESSSION and between-subject variables (SESSION X TREATMENT: 
[F (2, 54) = 0,827, p = 0.423], SESSION X SEX: [F (2, 54) = 0,092, p = 0.912], SESSION X 
TREATMENT X SEX: [F (2, 54) = 0,316, p = 0.730]). Furthermore, none of between-subject 
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variables showed significant effect (TREATMENT: F (1, 27) = 0,764, p = 0.390], SEX: F (1, 
27) = 0,090, p = 0.766], TREATMENT X SEX: F (1, 27) = 2,844, p = 0.103]). 
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Figure 11:  Mean escape latency (s) by session for each sub-group in Visually-cued task. 
 
 3.2.6. Control variables 
In addition, total distance moved by the rats (cm) and mean velocity (cm/s) in each trial by 
session were analysed. We show the data in Appendix D, and graphics in Appendix E. 
Neither treatment nor sex had got significant effect on total distance moved or mean velocity 
(p > 0.05) in almost all sessions. However, we found a significant effect of TREATMENT on 
velocity in the Visually-cued task [F (1, 27) = 5,562, P = 0.056]: the CPF-treated group 
showed a lower velocity compared to the control group. Data can be graphically seen in 
Figure 12: 
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Figure 12: Mean velocity (cm/s) by each treatment group in the Visually-cued task. 
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As we can see in Appendix E, although there are no significant treatment effects in other task, 
a trend towards lower mean velocity in CPF-exposed compared to that of the control group 
can be observed. 
4. DISCUSSION 
Our hypothesis was only partially confirmed in the case of the comparison between 
performance in Reinstating memory task and the last session of the Spatial learning task. 
Thus, we found that, after completing the Transfer task, control rats had a worsening in their 
spatial learning performance, whereas CPF-treated rats performed in a normal way. 
Moreover, although we can’t talk about significant differences between sexes in these control 
rats, we found that almost all the weight of the worsening effect may be attributed to the 
female rats, as they had higher escape latencies than males. Maybe we could have found 
significant differences increasing the number of rats by sub-group. In addition, when we 
analysed control variables, a general decrease in velocity was found in CPF-treated rats, in 
comparison to control rats, in one of the performed task (additionally, it seemed that there was 
a trend towards a velocity decrease in rats exposed to CPF). Moreover, the dose of CPF 
administered almost didn’t inhibit ChE activity, so we can’t attribute the found effects directly 
to a dysfunction in the ACh metabolism.  
We are going to talk firstly about the locomotor effect. As said, we observed a velocity 
decrease in CPF exposed rats, something that could be possibly interpreted as an anxiolytic 
effect. We have found other studies which provide evidence of anxiety reduction, such as 
Aldridge, Levin, Seidler, & Slotkin (2005), who described serotonergic receptors dysfunction 
related to an anxiolytic response, when CPF was administered on PND 1 to 4, although in this 
study that was tested with another type of protocol. Pope et al. (1992) also found a decrease in 
locomotor activity after an acute dose of CPF, yet activity restored in a few days after 
behavioural evaluation. Dam, Seidler and Slotkin (2000) registered lower locomotor activity 
in rats treated with 1 mg/kg on PND 1 to 4. For their part, Carr et al. (2001) observed a 
reduction in locomotor activity postnatally (PND 1-5 and 7-21), though doses used were 
higher than ours. However, Sánchez-Amate et al. (2001) reported an anxiety increase, after 
acute CPF exposure, in the plus maze (rats were 90 days old). Levin et al. (2002) described 
locomotor hyperactivity in prenatally CPF exposed rats, as well as Grabovska & Salyha 
(2015) detected ADHD-like behaviour (hyperactivity). Probably, differences between studies 
are caused, mainly, by different behavioural protocols. We also should note that consequences 
in neurochemical systems, as GABAergic or serotonergic ones, may depend on the period of 
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time exposed to CPF. In that way, maybe effects on this system are mainly anxiolytic when 
exposure is critically carried out in postnatal stage. Although we only found treatment effect 
in the Visually-cued task, it seemed that, in any way, exposure on PND 10 to 15 was effective 
(though less than in other studies, probably due to the combination of a less vulnerable 
neurochemical system and a behavioural evaluation in the old age). It would be interesting to 
carry out a study with different times of CPF administration, keeping the spatial learning 
measurements in the old age, in order to be able to compare it with our results. 
In respect of consequences on spatial learning, there already are studies in the scientific 
literature that proved a sexually-dimorphic effect of CPF on spatial learning. For example, in 
Gómez-Giménez et al. (2017), amongst rats exposed to CPF (and more pesticides), only CPF-
treated male rats had a worse spatial learning performance than control male rats, while as 
CPF didn’t affect performance of females compared to control female group. In fact, there 
was even an improvement in CPF-treated female rats when “exposed to 1mg/kg of 
chlorpyrifos”, in reference memory measured through ARM. However, male performance 
was generally better than female one, as can be expected of the spatial learning. In this study, 
exposition was carried out from GD 7 to PND 21.  For his part, Mamczarz et al. (2016) 
showed that only control male rats had a good performance when memory retention was 
measured, in a manner that CPF-treated male rats (prenatally exposed) performed as females. 
Moreover, Johnson et al. (2009) found that CPF only had negative effect when working 
memory performance of males was compared to the control males’ one, when exposed 
postnatally from PND 1 to PND 21. Levin et al. (2002) described contradictory data, showing 
that only CPF-treated females were impaired, although we should note that, in this case, they 
were exposed in gestational stage (GD 17 – 20). In fact, a year before, Levin et al. (2001) 
found a better performance in female CPF exposed rats, whereas males had got a worse 
performance (PND 1-4). On the other hand, in Maurissen et al. (2000) there was almost no 
effect of CPF exposure from GD 6 to LD (lactation day) 6 at low doses (including 1 mg/kg), 
though pups evaluated weren’t directly exposed to CPF in their PND (they received it by 
maternal milk). 
It’s clear that males, in general and biologically determined, have got a better spatial learning 
ability compared to the females, as it’s summarized in Rahman and Koerting (2008). In 
addition, it also seems that there are a critical period in which CPF exposure have more or less 
effect in spatial cognition, and that this effect is not the same for males and females. Gómez-
Gíménez et al. (2017) connected spatial learning and pro-inflammatory response in 
hippocampus after CPF exposure. They found an increase of pro-inflammatory interleukin B 
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in males exposed, but no in females. Moreover, there are multiple exogenous factors that can 
alter or disrupt the natural endocrine function, including the sexual hormones. In this sense, 
Maqbool, Mostafalou, Bahadar and Abdollahi (2016) talk about endocrine disrupting 
chemicals (EDC) that “are released into environment from different sources”, and mention 
studies, such as Fent and Stegeman (1991), or Fent (2003), in which different xeonobiotics 
alter the steroid hormones system. In fact, Buratti et al. (2011) found disruption (by a deficit) 
of aromatase activity (which aromatize testosterone (TST) into estradiol) and an increase in 
TST metabolites (product of TST hydrolysis by TST hydroxylase hormone) in rats exposed 
both prenatally and postnatally to low doses of CPF, in absence of AChE inhibition. 
Data exposed until now could suggest that CPF has got a masculinization effect, even when 
administered at doses not enough to induce ChE inhibition. In our study, control rats 
worsened their performance in spatial learning after the Transfer task (in which platform was 
removed), but we observed in descriptive statistics that this effect was evident, especially in 
females, yet there was no significant difference between sexes. Conversely, CPF-treated rats 
didn’t show a decrease in their performance. We also should have in account the age of 
animals when they were evaluated: 14 months old, almost senectitude. It’s likely that CPF 
possible effects dissipated when rats reached that old age, and possibly steroid hormones 
activity was completely restored at the beginning of spatial learning evaluation. However, 
females maybe were masculinized when they were exposed to CPF in synaptogenesis phase 
(remember that there are interdependence between endocrine and nervous systems); and we 
can also postulate a compensatory cholinergic mechanism (of course, not related to ChEs) that 
turned on in old age, which prevented the worse performance in CPF-exposed rats after the 
Transfer task. However, we should be cautious, as Levin et al. (2001) didn’t found any 
masculinization effect or improvement in females spatial learning when rats were exposed 
from PND 11 to 14 (very similar to the ours), although these effects emerged when rats were 
challenged with scopolamine. In order to confirm what was said, studies with a longer number 
of animals by sex and with measures of steroid hormones and aromatase should be developed. 
Moreover, in these studies spatial learning should be measured several times during the life of 
animals, so that we could verify the importance of the age and its relation with an early CPF 
exposure. It also would be interesting to introduce several administrations in different points 
of time, like cohorts.    
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5. CONCLUSIONS 
Further research is needed to prove effects of CPF in mammal neurodevelopment. Although 
our data doesn’t disagree with other provided by scientific literature, it’s evident that, at least, 
negative consequences, when measured in old age, aren’t as impairing as they could be in 
youth animals. Moreover, behavioural measures should be complemented with physiological 
data, in order to explain the cause of CPF-induced neurobehavioural deficits. In our case, it 
can’t be said that we found deficits: given that we found an absence of decrease in spatial 
learning performance, and a mild locomotor hypoactivity, we should even say that CPF 
enhanced performance. Additional studies could account for this effects, and tell us if there is 
any compensatory, long-term neurochemical mechanism that, either due or not, to CPF, 
underlies this data. Furthermore, we think that investigation on the relation between 
cholinergic and other neurochemical/hormonal systems will clarify the issue, giving us 
explanations alternative to those exclusively related to ACh metabolism and activity. 
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APPENDIX A: Physical-chemical characteristics of chlorpyrifos (CPF). 
 
 
Chemical characteristics of clorpyrifos 
Chemical name CAS: O,O-diethyl O-(3,5,6-trichloro-2-
pyridinyl) phosphorothioate 
ISO: CHLORPYRIFOS (ing.), 
CLORPIRIFOS (sp.) 
Chemical formula C9H11Cl3NO3PS 
Molecular weight 350,57 g/mol 
Melting point 41-43,5 ºC 
Boiling point ~ 160 ºC 
Vapor pressure at 25ºC 0,0025 Pa 
Water solubility at 25ºC 2 mg/L 
Organic solvent solubility 79% w/w in isooctane. 43% w/w in 
methanol 
Relative density (g/mL) 1,398 (at 43,5 ºC) 
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APPENDIX B: Characteristics of main studies about CPF exposure and spatial learning 
in MWM 
 
Age of exposure 
Spatial learning 
assessment 
Dosification Article 
Prenatal 
Post-natal 
days (PND) 
40-45 
25 mg/kg/day  x 10 days 
(s.c.) 
Mullins, Xu, Pereira, 
Prescrille et al. (2015) 
PND 38 25 mg/kg/day  x 10 days 
(s.c.) 
Mamczarz et al. 
(2016) 
1-2 months 
after CPF 
exposure 
1 mg/kg/day (GD 7 – 
PND 0) 
Gómez-Giménez et al. 
(2017) 
Posnatal 
Early 
PND 24 0.3/7 mg/kg (s.c.) 
Pre-weaning: PND 7, 11 
and 15. 
Post-weaning: PND 24, 
26 and 28. 
Jett, Navoa, Beckles & 
McLemore (2001) 
4 and a half 
months after 
CPF exposure 
10/15 mg/kg/day x 30 
days (s.c.) 
Terry, Beck, Warner, 
Vandenhuerk & 
Callahan (2012) 
1-2 months 
after CPF 
exposure 
1 mg/kg/day (PND 0- 21) Gómez-Giménez et al. 
(2017) 
11 months 
after exposure 
300 mg/kg (s.c.) Mullins, Xu, Pereira, 
Mamczarz et al. 
(2013) 
Adult 
1 or 14 days 
after CPF 
exposure 
2,5-100 mg/kg (s.c.) Terry et al. (2003) 
22 weeks after 
the second 
CPF exposure 
166/250 mg/kg Sánchez-Santed, 
Cañadas, Flores, 
López-Grancha & 
Cardona (2004) 
21 weeks after 
CPF exposure 
2 x 250 mg/kg (s.c.) Cañadas, Cardona, 
Dávila & Sánchez-
Santed (2005) 
16 hours after 
CPF exposure 
1, 5 o 10 mg/kg (gavage) Yan et al. (2012) 
72 hours/22 
weeks after 
CPF exposure 
25 mg/kg/día x 10 days 
(s.c.) 
López-Granero, 
Cardona, Giménez, 
Lozano, Barril, 
Aschner et al. (2014) 
7 months after 
CPF exposure 
5 mg/kg/day x 6 meses 
(diet) 
López-Granero, Ruiz-
Muñoz et al. (2016) 
¿? (non-specified) 
3 days after 
CPF exposure 
250 mg/kg (s.c.) López-Granero, 
Cañadas et al. (2013) 
21 weeks after 
CPF exposure 
5 mg/kg/day x 31 weeks 
(diet) 
López-Granero, 
Cardona, Giménez, 
Lozano, Barril, 
Sánchez-Santed et al. 
(2013) 
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APPENDIX C:  Characteristics of other studies using ARM to evaluate spatial learning 
after CPF exposure. 
Age of exposure 
Spatial learning 
assessment 
Dosification Article 
Prenatal PND 21 
1 / 5 mg/kg/day x 
4 days 
Levin et al. (2002) 
Posnatal Temprana PND 29-60 
Progressive (1 to 6 
mg/kg/day x 21 
days (gavage)) 
Johnson, 
Chambers, Nail, 
Givaruangsawat & 
Carr (2009) 
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APPENDIX D: Control variables data. 
 
Table A1: Effects of each variable on total distance moved in the Spatial learning task. 
 
 
Note: The accepted level of significance for analyses was p ≤ 0,05.   
 
 
 
 
 
 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 0.107 1 0.747 
SEX 1.375 1 0.251 
Error  1  
Within-subjects 
TRIAL 36.593 1.980 0.000 
Error (TRIAL)  53.447  
SESSION 23.980 7 0.000 
Error (SESSION)  189  
Interactions 
TREATMENT * SEX 1.311 1 0.262 
TRIAL * TREATMENT 0.747 1.980 0.477 
TRIAL*SEX 0.123 1.980 0.883 
TRIAL*TREATMENT * SEX 0.618 1.980 0.541 
SESSION * TREATMENT 0.604 7 0.752 
SESSION*SEX 3.144 7 0.004 
SESSION*TREATMENT* 
SEX 
0.344 7 0.933 
TRIAL*SESSION 3.174 10.346 0.001 
TRIAL*SESSION*TREATMENT 0.445 10.346 0.928 
TRIAL*SESSION*SEX 1.148 10.346 0.325 
TRIAL*SESSION * 
TREATMENT* SEX 
0.950 10.346 0.490 
ERROR (TRIAL * SESSION)  279.337  
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Table A2: Effect of each variable on velocity (mean) in the Spatial learning task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 3.951 1 0.057 
SEX 0.206 1 0.654 
Error  27  
Within-subjects 
TRIAL 21.281 1.975 0.000 
Error (TRIAL)  53.325  
SESSION 9.903 4.768 0.000 
Error (SESSION)  128.735  
Interactions 
TREATMENT * SEX 0.001 1 0.975 
TRIAL * TREATMENT 0.455 1,975 0.634 
TRIAL*SEX 1.289 1.975 0.284 
TRIAL*TREATMENT * SEX 1.702 1.975 0.192 
SESSION * TREATMENT 0.900 4.768 0.480 
SESSION*SEX 1.369 4.768 0.242 
SESSION*TREATMENT* 
SEX 
2.029 4.768 0.082 
TRIAL*SESSION 6.358 11.138 0.000 
TRIAL*SESSION*TREATMENT 0.540 11.138 0.877 
TRIAL*SESSION*SEX 1.442 11.138 0.152 
TRIAL*SESSION * 
TREATMENT* SEX 
1.341 11.138 0.200 
ERROR (TRIAL * SESSION)  300.737  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
 
 
 
 
Table A3: Effects of between-subject variables on total distance moved in the Transfer task. 
FACTOR F Deg. of freedom Sig. 
TREATMENT 0.237 1 0.630 
SEX 0.396 1 0.534 
TREATMENT * SEX 0.020 1 0.888 
Error  27  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A4: Effects of between-subject variables on velocity (mean) in the Transfer task. 
FACTOR F Deg. of freedom Sig. 
TREATMENT 0.557 1 0.462 
SEX 0.211 1 0.650 
TREATMENT * SEX 0.111 1 0.742 
Error  27  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
 
 
Table A5: Effects of each variable on total distance moved in the Reinstating memory task 
compared to the last session of Spatial learning task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 0.952 1 0.338 
SEX 0.007 1 0.933 
Error  27  
Within-subjects 
TRIAL 2.599 3 0.058 
Error (TRIAL)  81  
SESSION 1.402 1 0.247 
Error (SESSION)  27  
Interactions 
TREATMENT * SEX 0.033 1 0.858 
TRIAL * TREATMENT 0.368 3 0.776 
TRIAL*SEX 0.249 3 0.862 
TRIAL*TREATMENT * SEX 0.963 3 0.415 
SESSION * TREATMENT 3.847 1 0.060 
SESSION*SEX 0.495 1 0.488 
SESSION*TREATMENT* 
SEX 
1.016 1 0.322 
TRIAL*SESSION 0.870 2.297 0.437 
TRIAL*SESSION*TREATMENT 0.548 2.297 0.605 
TRIAL*SESSION*SEX 2.048 2.297 0.131 
TRIAL*SESSION * 
TREATMENT* SEX 
0.275 2.297 0.790 
ERROR (TRIAL * SESSION)  62.030  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A6: Effects of each variable on velocity (mean) in the Reinstating memory task 
compared to the last session of Spatial learning task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 1.446 1 0.240 
SEX 0.308 1 0.583 
Error  27  
Within-subjects 
TRIAL 1.354 3 0.263 
Error (TRIAL)  81  
SESSION 1.906 1 0.179 
Error (SESSION)  27  
Interactions 
TREATMENT * SEX 0.403 1 0.531 
TRIAL * TREATMENT 0.901 3 0.444 
TRIAL*SEX 2.628 3 0.056 
TRIAL*TREATMENT * SEX 0.924 3 0.433 
SESSION * TREATMENT 0.042 1 0.839 
SESSION*SEX 0.143 1 0.709 
SESSION*TREATMENT* 
SEX 
0.276 1 0.603 
TRIAL*SESSION 1.462 3 0.231 
TRIAL*SESSION*TREATMENT 0.886 3 0.452 
TRIAL*SESSION*SEX 4.427 3 0.006 
TRIAL*SESSION * 
TREATMENT* SEX 
1.334 3 0.269 
ERROR (TRIAL * SESSION)  81  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A7: Effect of each variable on total distance moved in Reversal task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 1.181 1 0.287 
SEX 0.434 1 0.516 
Error  27  
Within-subjects 
TRIAL 15.698 2.255 0.000 
Error (TRIAL)  60.890  
SESSION 4.360 2 0.018 
Error (SESSION)  54  
Interactions 
TREATMENT * SEX 0.115 1 0.737 
TRIAL * TREATMENT 0.420 2.255 0.683 
TRIAL*SEX 1.829 2.255 0.165 
TRIAL*TREATMENT * SEX 0.648 2.255 0.545 
SESSION * TREATMENT 0.086 2 0.918 
SESSION*SEX 0.673 2 0.514 
SESSION*TREATMENT* 
SEX 
1.402 2 0.255 
TRIAL*SESSION 0.887 3.722 0.469 
TRIAL*SESSION*TREATMENT 0.783 3.722 0.531 
TRIAL*SESSION*SEX 0.680 3.722 0.597 
TRIAL*SESSION * 
TREATMENT* SEX 
1.428 3.722 0.233 
ERROR (TRIAL * SESSION)  100.506  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A8: Effect of each variable on velocity (mean) in Reversal task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 0.840 1 0.368 
SEX 0.012 1 0.913 
Error  27  
Within-subjects 
TRIAL 1.766 2.267 0.175 
Error (TRIAL)  61.198  
SESSION 2.966 2 0.060 
Error (SESSION)  54  
Interactions 
TREATMENT * SEX 0.154 1 0.698 
TRIAL * TREATMENT 0.434 2.267 0.675 
TRIAL*SEX 0.157 2.267 0.879 
TRIAL*TREATMENT * SEX 0.729 2.267 0.503 
SESSION * TREATMENT 0.379 2 0.261 
SESSION*SEX 0.382 2 0.685 
SESSION*TREATMENT* 
SEX 
0.772 2 0.467 
TRIAL*SESSION 1.142 4.324 0.341 
TRIAL*SESSION*TREATMENT 2.164 4.324 0.072 
TRIAL*SESSION*SEX 0.246 4.324 0.923 
TRIAL*SESSION * 
TREATMENT* SEX 
1.977 4.324 0.097 
ERROR (TRIAL * SESSION)  116.745  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A9: Effect of each variable on total distance moved in Visually-cued task. 
FACTOR F 
Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 0.867 1 0.360 
SEX 1.891 1 0.180 
Error  27  
Within-subjects TRIAL 2.901 3 0.040 
Error (TRIAL)  81  
SESSION 4.150 2 0.021 
Error (SESSION)    
Interactions TREATMENT * SEX 2.918 1 0.099 
TRIAL * TREATMENT 0.230 3 0.876 
TRIAL*SEX 0.915 3 0.437 
TRIAL*TREATMENT * SEX 0.535 3 0.660 
SESSION * TREATMENT 1.711 2 0.190 
SESSION*SEX 0.189 2 0.828 
SESSION*TREATMENT* 
SEX 
0.274 2 0.762 
TRIAL*SESSION 8.435 3.986 0.000 
TRIAL*SESSION*TREATMENT 0.303 3.986 0.875 
TRIAL*SESSION*SEX 0.581 3.986 0.677 
TRIAL*SESSION * 
TREATMENT* SEX 
1.798 3.986 0.135 
ERROR (TRIAL * SESSION)  107.627  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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Table A10: Effect of each variable on velocity (mean) in Visually-cued task. 
FACTOR F Deg. of 
freedom 
Sig. 
Between-
subjects 
TREATMENT 5.562 1 0.026 
SEX 0.910 1 0.349 
Error  27  
Within-subjects TRIAL 3.222 3 0.027 
Error (TRIAL)  81  
SESSION 4 1.620 0.033 
Error (SESSION)  43.727  
Interactions TREATMENT * SEX 0.004 1 0.950 
TRIAL * TREATMENT 0.098 3 0.961 
TRIAL*SEX 0.824 3 0.485 
TRIAL*TREATMENT * SEX 0.884 3 0.453 
SESSION * TREATMENT 0.060 1.620 0.910 
SESSION*SEX 0.029 1.620 0.949 
SESSION*TREATMENT* 
SEX 
0.170 1.620 0.799 
TRIAL*SESSION 0.285 3.983 0.887 
TRIAL*SESSION*TREATMENT 1.007 3.983 0.407 
TRIAL*SESSION*SEX 0.602 3.983 0.661 
TRIAL*SESSION * 
TREATMENT* SEX 
0.266 3.983 0.898 
ERROR (TRIAL * SESSION)  107.534  
Note: The accepted level of significance for analyses was p ≤ 0,05.   
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APPENDIX E: Control variables graphics. 
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Figure B1: Total distance moved (cm) by each treatment group in Spatial learning task. 
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Figure B2: Mean velocity (cm/s) by each treatment group in Spatial learning task. 
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Figure B3: Total distance moved (cm) by each treatment group in Transfer task. 
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Figure B4: Mean velocity (cm/s) by each treatment group in Transfer task.. 
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Figure B5: Total distance moved (cm) by each treatment group in the last session of Spatial 
learning task (S8) compared to the Reinstating memory task. 
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Figure B6: Mean velocity (cm/s) by each treatment group in the last session of Spatial 
learning task (S8) compared to the Reinstating memory task. 
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Figure B7: Total distance moved (cm) by each treatment group in Reversal group. 
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Figure B8: Mean velocity (cm/s) by each treatment group in Reversal task.. 
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Figure B9: Total distance moved (cm) by each treatment group in Visually-cued task. 
 
 
 
 
